Skip to Content
Merck
CN

SAB4504567

Anti-phospho-VEGFR2 (pTyr1175) antibody produced in rabbit

affinity isolated antibody

Synonym(s):

Anti-CD309, Anti-FLK1, Anti-VEGFR, Anti-VEGFR2

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

NACRES:
NA.41
UNSPSC Code:
12352203
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Anti-phospho-VEGFR2 (pTyr1175) antibody produced in rabbit, affinity isolated antibody

biological source

rabbit

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

mol wt

antigen 151 kDa

species reactivity

human, rat, mouse

concentration

~1 mg/mL

technique(s)

ELISA: 1:10000
immunohistochemistry: 1:50-1:100
western blot: 1:500-1:1000

NCBI accession no.

UniProt accession no.

shipped in

wet ice

storage temp.

−20°C

target post-translational modification

phosphorylation (pTyr1175)

Quality Level

Gene Information

human ... KDR(3791)

Application

Anti-phospho-VEGFR2 (pTyr1175) antibody has been used in immunoblotting.

Biochem/physiol Actions

The immunoglobulin-like (Ig-like) domains of the vascular endothelial growth factor receptor-2 (VEGFR-2) are essential for specific ligand binding and receptor dimerization. It helps to activate multiple signaling cascades. VEGF-KDR participates in angiogenesis. VEGFR2 is involved in progression of several cancers like gliomas, malignant peripheral nerve sheath tumors, triple-negative breast cancer (TNBC) and gastrointestinal stromal tumors (GISTs).

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

General description

The vascular endothelial growth factor receptor-2 (VEGFR-2) is also called as kinase insert domain containing receptor (KDR). There are seven immunoglobulin-like (Ig-like) domains at the extracellular region (EC) of VEGFR-2. This gene is mapped to human chromosome 4q12.

Immunogen

The antiserum was produced against synthesized peptide derived from human VEGFR2 around the phosphorylation site of Tyr1175.

Immunogen Range: 1141-1190

Physical form

Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class

10 - Combustible liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

常规特殊物品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

VEGF165b modulates endothelial VEGFR1-STAT3 signaling pathway and angiogenesis in human and experimental peripheral arterial disease.
Ganta VC, et al.
Circulation Research (2016)
Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme.
Holtkamp N, et al.
Neuro-Oncology, 9(3), 291-297 (2007)
Vijay Chaitanya Ganta et al.
Circulation research, 120(2), 282-295 (2016-12-16)
Atherosclerotic-arterial occlusions decrease tissue perfusion causing ischemia to lower limbs in patients with peripheral arterial disease (PAD). Ischemia in muscle induces an angiogenic response, but the magnitude of this response is frequently inadequate to meet tissue perfusion requirements. Alternate splicing
Immunoglobulin-like domain 4-mediated ligand-independent dimerization triggers VEGFR-2 activation in HUVECs and VEGFR2-positive breast cancer cells.
Zhang S, et al.
Breast Cancer Research and Treatment, 163(3), 423-434 (2017)
Vascular endothelial growth factor receptor-2 polymorphisms have protective effect against the development of tendinopathy in volleyball athletes.
Salles JI, et al.
PLoS ONE, 11(12), e0167717-e0167717 (2016)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service